- Home
- SAVA vs INVE Comparison
SAVA vs INVE Comparison
Compare SAVA & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- INVE
- Stock Information
- Founded
- SAVA 1998
- INVE 1990
- Country
- SAVA United States
- INVE United States
- Employees
- SAVA N/A
- INVE N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- INVE Computer peripheral equipment
- Sector
- SAVA Health Care
- INVE Technology
- Exchange
- SAVA Nasdaq
- INVE Nasdaq
- Market Cap
- SAVA 102.4M
- INVE 85.9M
- IPO Year
- SAVA N/A
- INVE 1997
- Fundamental
- Price
- SAVA $3.63
- INVE $3.58
- Analyst Decision
- SAVA Hold
- INVE Strong Buy
- Analyst Count
- SAVA 1
- INVE 2
- Target Price
- SAVA $2.00
- INVE $5.50
- AVG Volume (30 Days)
- SAVA 4.9M
- INVE 27.7K
- Earning Date
- SAVA 11-06-2025
- INVE 11-06-2025
- Dividend Yield
- SAVA N/A
- INVE N/A
- EPS Growth
- SAVA N/A
- INVE N/A
- EPS
- SAVA N/A
- INVE 3.12
- Revenue
- SAVA N/A
- INVE $23,538,000.00
- Revenue This Year
- SAVA N/A
- INVE N/A
- Revenue Next Year
- SAVA N/A
- INVE $9.06
- P/E Ratio
- SAVA N/A
- INVE $1.15
- Revenue Growth
- SAVA N/A
- INVE N/A
- 52 Week Low
- SAVA $1.15
- INVE $2.86
- 52 Week High
- SAVA $33.98
- INVE $4.29
- Technical
- Relative Strength Index (RSI)
- SAVA 72.05
- INVE 47.69
- Support Level
- SAVA $2.85
- INVE $3.33
- Resistance Level
- SAVA $3.66
- INVE $3.80
- Average True Range (ATR)
- SAVA 0.34
- INVE 0.17
- MACD
- SAVA 0.10
- INVE -0.02
- Stochastic Oscillator
- SAVA 92.90
- INVE 51.02
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.